## Core Concept
The question tests the understanding of fibrinolysis and the role of various factors in this process. **Plasminogen activators** are substances that convert plasminogen into plasmin, an enzyme involved in the breakdown of blood clots. The regulation of plasminogen activators is crucial for preventing excessive bleeding or thrombosis.

## Why the Correct Answer is Right
The correct answer, ε-Aminocaproic acid (ACA), is an **antifibrinolytic agent**. It works by inhibiting the activation of plasminogen to plasmin, thereby preventing the breakdown of clots. ε-Aminocaproic acid competes with the lysine binding sites on plasminogen, which are necessary for its activation by plasminogen activators. By doing so, it effectively prevents the action of plasminogen activators.

## Why Each Wrong Option is Incorrect
- **Option A:** Tranexamic acid is also an antifibrinolytic agent but specifying whether it's correct or not requires understanding its mechanism. It works similarly to ε-Aminocaproic acid but is more potent and has a longer duration of action. However, it is not the correct answer provided.
- **Option B:** Aminomethylbenzoic acid (AMBA) is another antifibrinolytic agent. Like ε-Aminocaproic acid, it inhibits fibrinolysis but through a slightly different mechanism. It's not specified as the correct answer here.
- **Option D:** Protamines are used to reverse the effects of heparin, an anticoagulant, and do not play a role in preventing the action of plasminogen activators.

## Clinical Pearl / High-Yield Fact
A key point to remember is that ε-Aminocaproic acid (ACA) and tranexamic acid are used clinically to manage or prevent excessive bleeding due to conditions like hemophilia or during surgeries. Tranexamic acid, in particular, has gained attention for its efficacy in reducing mortality from bleeding in trauma patients.

## Correct Answer: C. ε-Aminocaproic acid.